Hasan Ravari; Azin Banihashem; Mohammad Vejdani; Gholamhosein Kazemzadeh
Abstract
Vascular access failure is known as a principal cause of morbidity of end stage renal disease (ESRD) patients. The major reason for vascular access failure is the neointimal hyperplasia which leads to venous thrombosis and stenosis. The efficacy of different pharmacological therapies has been studied ...
Read More
Vascular access failure is known as a principal cause of morbidity of end stage renal disease (ESRD) patients. The major reason for vascular access failure is the neointimal hyperplasia which leads to venous thrombosis and stenosis. The efficacy of different pharmacological therapies has been studied in increasing the vascular access patency duration or decreasing the thrombosis of arteriovenous grafts or fistulas. In the current review, we reviewed the results obtained in different randomized control trials considering the efficacy of pharmacotherapy on the thrombosis rate and duration of vascular access grafts patency in HD patients.